Statistics on Biotechnology Use  
Results by sector of operation
Company sector.  Biotechnology results by main variables by whichever Biotechnology activities are the main ones, secondary or a tool necessary for production
Unidades: specified in variables

;Total;Main;Secondary dwellings;Tool;
Companies that carry out R&D in Biotechnology;1.078;526;173;379;
%Companies according to biotechnology used: Genetic code;35;45;22;27;
%Companies according to biotechnology used: Functional units;42;52;37;30;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;27;34;22;19;
%Companies according to biotechnology used: Bioprocesses;49;43;51;56;
%Companies according to biotechnology used: Sub-cellular organisms;8;12;6;4;
%Companies according to biotechnology used: Bio-computing;22;33;17;9;
%Companies according to biotechnology used: Nanobiotechnology;14;19;15;6;
%Companies according to biotechnology used: Other;12;13;14;10;
%Company by field(s) of ultimate application of biotechnology use: Human Health;48;68;39;25;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;20;21;20;19;
%Company by field(s) of ultimate application of biotechnology use: Food products;33;26;30;44;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;24;22;28;25;
%Company by field(s) of ultimate application of biotechnology use: Environment;15;12;26;14;
%Company by field(s) of ultimate application of biotechnology use: Industry;14;14;20;9;
Personnel in R&D in biotechnology (no. of persons);10.191;5.753;1.481;2.956;
Personnel in R&D in biotechnology (no. of persons): Researchers;5.774;3.440;849;1.485;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;4.417;2.314;632;1.471;
Personnel in R&D in biotechnology (no. of persons): women;5.525;3.332;769;1.424;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;3.015;1.902;419;694;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;2.511;1.431;350;730;
Personnel in R&D in biotechnology (FTE);7.191,4;4.611,5;889,5;1.690,4;
Personnel in R&D in biotechnology (FTE): Researchers;4.276,6;2.783,2;566;927,5;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;2.914,7;1.828,3;323,5;763;
Personnel in R&D in biotechnology (FTE): women;3.985,4;2.631,7;473,6;880,2;
Personnel in R&D in biotechnology (FTE): (women) Researchers;2.234;1.505,4;276,8;451,8;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;1.751,4;1.126,3;196,7;428,4;
Internal expenditure on R&D (thousands of euros);578.171;392.202;77.155;108.814;
1) By nature of the expense: Current expenses;517.601;345.782;70.758;101.061;
1.1) Remuneration to researchers;213.755;144.473;30.720;38.563;
1.2) Remuneration to technicians and assistants;98.440;61.637;11.993;24.810;
1.3) Other current expenses;205.406;139.672;28.045;37.689;
2) By nature of the expense: Capital expenses;60.570;46.420;6.397;7.753;
2.1) Land and buildings;22.609;21.900;79;630;
2.2) Equipment and instruments;36.169;23.279;6.254;6.636;
2.3) Acquisition of specific R+D software;1.793;1.242;63;488;
1) By origin of the funds: National funds;487.615;312.995;69.889;104.731;
1.1) Own funds;330.459;205.081;45.123;80.255;
1.2) From companies;45.462;23.837;13.797;7.827;
1.3) Public Administration funds;66.189;40.409;10.721;15.060;
1.4) From Universities;25.148;25.101;32;15;
1.5) From non profit private institutions;20.357;18.567;216;1.575;
1) By origin of the funds: Foreign funds;90.556;79.207;7.266;4.083;
2.1) From EU programmes;20.932;15.392;3.369;2.172;
2.2) Other foreign funds;69.624;63.816;3.897;1.911;
Purchase of R&D services in biotechnology (thousands of euros);166.022;131.839;27.652;6.530;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;97.455;77.835;14.188;5.432;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;68.567;54.005;13.464;1.098;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;46;56;45;33;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;13;12;17;13;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;14;14;19;12;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;14;14;22;10;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of access to international markets;17;20;23;12;
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of distribution and sales channels;17;20;21;11;
%Companies that consider the following obstacles as very important considering biotechnology development : Acceptance / public perception;18;18;23;17;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;35;39;41;28;
%Companies that consider the following obstacles as very important considering biotechnology development : Time / cost;49;54;49;41;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;21;21;21;21;
% Companies that have requested biotechnology patents;15;24;10;7;
Number of patents requested;526;397;72;57;
% Companies with income of an international origin related to biotechnological activities;26;35,9;12,8;18,2;
% Turnover representing income of an international origin related to biotechnological activities;1,4;11,7;.;0,9;
% Income of of an international origin related to biotechnological activities distributed in: Income received from the EU;63,8;66,2;73;49,7;
% Income of of an international origin related to biotechnological activities distributed in: Income received from other countries;36,2;33,8;27,1;50,3;
% Income of of an international origin related to biotechnological activities by classification: Internacional trade in products and services;91,6;91,3;64,7;95,1;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;0,9;0,6;.;3,1;
% Income of an international origin related with activities according to the classification: Operating source abroad;1,9;1,6;34,9;1,4;
% Income of an international origin related with activities according to the classification: Other;5,6;6,6;0,4;0,5;
Notas:

.
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute